

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-19. (cancelled)

20. (currently amended) An isolated peptide consisting of an amino acid sequence ~~at least 90% identical to~~ SEQ ID NO: 2 or SEQ ID NO: 3, ~~and exhibiting an angiogenesis inhibiting activity and a capacity for binding to glycoaminoglycans (GAG).~~

21-26. (cancelled)

27. (currently amended) A pharmaceutical composition comprising [[the]] an isolated peptide of claim 20 consisting of an amino acid sequence SEQ ID NO: 2 or SEQ ID NO: 3, and at least one pharmaceutically acceptable excipient.

28. (currently amended) The pharmaceutical composition of claim 27, further comprising a peptide consisting of an amino acid sequence ~~at least 90% identical to of~~ SEQ ID NO: 4, ~~and exhibiting an angiogenesis inhibiting activity and a capacity for binding to the ALK receptor.~~

29. (cancelled)

30. (previously presented) The pharmaceutical composition of claim 28, comprising:

(a) the peptide consisting of the amino acid sequence of SEQ ID NO: 2;

(b) the peptide consisting of the amino acid sequence of SEQ ID NO: 3; and

(c) the peptide consisting of the amino acid sequence of SEQ ID NO: 4.

31-34. (cancelled)

35. (currently amended) A method for preparing a medicament for the treatment of ~~a pathology associated with an angiogenesis tumors~~, comprising adding [[the]] an isolated peptide ~~of claim 20 consisting of an amino acid sequence SEQ ID NO: 2 or SEQ ID NO: 3~~ to a pharmaceutically acceptable vehicle.

36. (currently amended) The method of claim 35, wherein said isolated peptide is combined with a second peptide consisting of an amino acid sequence ~~at least 90% identical to of SEQ ID NO: 4, and exhibiting an angiogenesis inhibiting activity and a capacity for binding to the ALK receptor.~~

37-41. (cancelled)